Our Carboxyl Terminal Peptide (CTP) technology is used to extend the half-lives of pharmacologically active proteins. CTP uses recombinant technology to fuse a short, naturally occurring 28 amino acid sequence (a CTP) to a pharmacologically active protein which results in slower excretion of the therapeutic protein, thus, extending the protein's half-life. At OPKO, we are currently use CTP technology to treat growth hormone deficiency and in our Factor VIIa product for the management of hemophilia A & B.
Our reversible PEGylation technology is a novel technique for creating extended release therapeutics. In reversible PEGylation, a conjugate is formed through a proprietary bi-functional hydrolyzable linker, between a drug that contains a primary peptide and a polyethylene glycol (PEG) chain. Once the conjugate enters the bloodstream the linker hydrolyzes at physiological pH and body temperature, releasing the intact drug in a controlled manner. Depending on the peptide or protein, the released molecule can either work locally, systemically or cross the blood brain barrier at receptor sites.
The Claros® 1 device is a point-of-care, bench top diagnostic instrument system designed to provide rapid, quantitative blood test results in 15 minutes, right in the physician's office, using a fingerstick of whole blood. The Sangia Total PSA Claros® 1 test, which provides measurements comparable to large instruments used in central reference laboratories, received FDA approval in January 2019. Additional test menu options for this platform are planned for future regulatory approval.